// App-Quantinova.ai

: Target engagement confirmed in man with a dipeptidyl peptidase 1 inhibitor

Researchers

Presenter

  • Kristina Stenvall

Principal Investigators

  • John Mo

  • Muir Russel

  • Philip Gardiner

  • Robert Palmer

  • Alexandra Jauhiainen

  • Jukka Maenpaa

  • James Root

  • Bengt Larsson

Medical Centers

  • Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden

  • Personalised Healthcare and Biomarkers, Innovative Medicines and Early Development, AstraZenecatory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca, Cambridge, United Kingdom

  • Early Clinical Development, AstraZeneca, Gothenburg, Sweden,

  • Patient Safety, Respiratory, Inflammation, Autoimmunity, Infections and Vaccines Therapeutic Area, AstraZeneca, Gothenburg, Sweden

Locations

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • AZD-7986

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved